• 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br Acknowledgments We are grateful to the participants of th


    Acknowledgments: We are grateful to the participants of the Southern Community Cohort Study for their dedicated participation in the study.
    Appendix A. Supplementary data
    [1] US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2018;319:1901–13.
    [2] Preston MA, Batista JL, Wilson KM, et al. Baseline prostate-specific antigen levels in midlife predict lethal prostate cancer. J Clin Oncol 2016;34:2705–11.
    [3] Chornokur G, Dalton K, Borysova ME, 11024-24-1 Kumar NB. Disparities at presentation, diagnosis, treatment, and survival in African Ameri-can men, affected by prostate cancer. Prostate 2011;71:985–97.
    [5] Ross KS, Carter HB, Pearson JD, Guess HA. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 2000;284:1399–405.
    [6] Jahn JL, Giovannucci E, Stampfer MJ. The high prevalence of undi-agnosed prostate cancer at autopsy: Implications for epidemiology and treatment of prostate cancer in the prostate-specific antigen-era. Int J Can 2015;137:2795–802.
    [7] Zlotta AR, Egawa S, Pushkar D, et al. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst 2013;105:1050–8.
    [8] Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of 11024-24-1 and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995;154:407–13. [9] Whittemore AS, Lele C, Friedman GD, Stamey T, Vogelman JH, Orentreich N. Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst 1995;87:354–60. 
    [10] Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 2001;58:411–6.
    [11] Whittemore AS, Cirillo PM, Feldman D, Cohn BA. Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. J Urol 2005;174:872–6, discussion 6.
    [12] Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 2006;67:316–20. [13] Kuller LH, Thomas A, Grandits G, Neaton JD. Elevated prostate-specific antigen levels up to 25 years prior to death from prostate cancer. Cancer Epidemiol Biomarkers Prev 2004;13:373–7.
    [15] Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ 2013;346:f2023.
    [16] Stattin P, Vickers AJ, Sjoberg DD, et al. Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of kallikrein markers: a nested case-control study. Eur Urol 2015;68:207–13.
    [17] Vickers AJ, Cronin AM, Bjork T, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 2010;341:c4521. [18] Signorello LB, Hargreaves MK, Blot WJ. The Southern Community Cohort Study: investigating health disparities. J Health Care Poor Underserved 2010;21:26–37.
    [19] Vickers AJ, Gupta A, Savage CJ, et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort fol-lowed for 15 years without screening. Cancer Epidemiol Biomarkers Prev 2011;20:255–61.
    [20] Ulmert D, Becker C, Nilsson JA, et al. Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem 2006;52:235–9.
    [23] American Cancer Society Recommendations for Prostate Cancer Early Detection. 2016. prostate-cancer/early-detection/acs-recommendations.html.
    [24] American Urological Association. Early Detection of Prostate Can-cer. 2015.
    [25] Vertosick EA, Poon BY, Vickers AJ. Relative value of race, family history and prostate-specific antigen as indications for early initia-tion of prostate cancer screening. J Urol 2014;192:724–9.
    [26] Fowke JH, Signorello LB, Chang SS, et al. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer 2006;107:2361–7.